New Japanese encephalitis vaccines: alternatives to production in mouse brain

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine

(2011) Peter E Nasveld et al.   Human vaccines & immunotherapeutics

Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine

(2011) Peter E. Nasveld et al.   Human vaccines & immunotherapeutics

Japanese Encephalitis in Travelers from Non-Endemic Countries, 1973–2008

(2010) Susan L. Hills et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Combating Japanese encephalitis: Vero-cell derived inactivated vaccines and the situation in Japan

(2010) Tomohiro Ishikawa et al.   Future Virology

Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-olds

(2010) Kulkanya Chokephaibulkit et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up

(2010) Katrin Dubischar-Kastner et al.   VACCINE

Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51

(2010) Katrin Dubischar-Kastner et al.   VACCINE

A cost–effectiveness analysis of Japanese encephalitis vaccine in Cambodia

(2010) Sok Touch et al.   VACCINE

Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials

(2010) Joseph Torresi et al.   VACCINE

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities

(2010) Yongxin Yu   VACCINE

Randomized, Controlled Trial of Oral Ribavirin for Japanese Encephalitis in Children in Uttar Pradesh, India

(2009) Rashmi Kumar et al.   CLINICAL INFECTIOUS DISEASES

IC51 Japanese Encephalitis vaccine

(2009) Herwig Kollaritsch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Japanese Encephalitis: Defining Risk Incidence for Travelers to Endemic Countries and Vaccine Prescribing From the UK and Switzerland: Table 1

(2009) Christoph Hatz et al.   JOURNAL OF TRAVEL MEDICINE

Japanese Encephalitis in Travelers: Review of Cases and Seasonal Risk

(2009) Mads R. Buhl et al.   JOURNAL OF TRAVEL MEDICINE

Effectiveness of One Dose of SA 14-14-2 Vaccine against Japanese Encephalitis

(2009) Rashmi Kumar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study

(2009) Elisabeth Schuller et al.   VACCINE

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study

(2009) A. Kaltenböck et al.   VACCINE

Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age

(2009) A. Kaltenböck et al.   VACCINE

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

(2009) Bruno Guy et al.   VACCINE

Japanese encephalitis vaccine in travelers

(2008) Tomas Jelinek   Expert Review of Vaccines

Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand

(2008) Ville A. Lehtinen et al.   JOURNAL OF CLINICAL VIROLOGY

Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis Vaccine

(2008) E. Tauber et al.   JOURNAL OF INFECTIOUS DISEASES

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51

(2008) E. Schuller et al.   VACCINE

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51

(2008) Elisabeth Schuller et al.   VACCINE

Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia

(2008) Wei Liu et al.   VACCINE

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

(2008) Salvacion Gatchalian et al.   VACCINE

Japanese encephalitis and vaccines: past and future prospects

(2008) Maria Paulke-Korinek et al.   WIENER KLINISCHE WOCHENSCHRIFT